Inadvertent administration of intravenous ziprasidone leading to bradycardia and QT interval prolongation

Annals of Pharmacotherapy

Volumn 42, Issue 6, 2008, Pages 902-903

  Bentley, Michael L ^a,b   Biscardi, Frank H ^a,c   Butcher, Christian ^d   Levitov, Alexander ^d,e  

^a CARILION CLINIC   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c Carilion Clinical Sleep Center

^d Department of Medicine

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATROPINE; ZIPRASIDONE;

ADULT; CASE REPORT; FEMALE; HUMAN; LETTER; MENTAL DEFICIENCY; PRIORITY JOURNAL; QT PROLONGATION; SINUS BRADYCARDIA; THOUGHT DISORDER;

ADULT; ANTIPSYCHOTIC AGENTS; BRADYCARDIA; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAVENOUS; LONG QT SYNDROME; MEDICATION ERRORS; PIPERAZINES; THIAZOLES;

EID: 44649155173     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L170     Document Type: Letter

References (5)

1. Manini A, Raspberry D, Hoffman R, Nelson L. QT prolongation and torsades de pointes following overdose of ziprasidone and amantadine. J Med Toxicol 2007;3:178-81.
2. Haddad P, Anderson I. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 2002;62:1649-71.
3. Young C, Lujan E. Intravenous ziprasidone for treatment of delirium in the intensive care unit. Anesthesiology 2004;101:794-5.
4. Miceli JJ, Wilner KD, Swan SK, Tensfeldt TG. Pharmacokinetics, safety, and tolerability of intramuscular ziprasidone in healthy volunteers. J Clin Pharmacol 2005;45:620-30.
5. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.